COGT (Cogent Biosciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by COGT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-06 | Karen Jean Ferrante | Director | A | — | — |
| 2026-06-11 | Arlene Morris | Director | A | — | — |
| 2026-06-11 | CHRISTOPHER W. CAIN | Director | A | — | — |
| 2026-06-11 | Karen Jean Ferrante | Director | A | — | — |
| 2026-06-11 | Matthew Ros | Director | A | — | — |
| 2026-06-11 | Peter Evan Harwin | Director | A | — | — |
| 2026-06-11 | Todd Shegog | Director | A | — | — |
| 2026-05-21 | Andrew R Robbins | President and CEO | G | — | — |
| 2026-04-03 | Karen Jean Ferrante | Director | A | — | — |
| 2026-01-22 | Fairmount Funds Management LLC | Director | Sell | — | — |
| 2026-01-05 | Karen Jean Ferrante | Director | A | — | — |
| 2025-12-30 | Jessica Sachs | Chief Medical Officer | Sell | — | — |
| 2025-12-30 | Evan Kearns | Chief Legal Officer | Sell | — | — |
| 2025-12-30 | John Edward Robinson | Chief Scientific Officer | Sell | — | — |
| 2025-12-30 | John L. Green | Chief Financial Officer | Sell | — | — |
| 2025-12-19 | John L. Green | Chief Financial Officer | MIXED | — | — |
| 2025-12-19 | Jessica Sachs | Chief Medical Officer | MIXED | — | — |
| 2025-12-19 | Andrew R Robbins | President and CEO | MIXED | — | — |
| 2025-12-19 | Evan Kearns | Chief Legal Officer | MIXED | — | — |
| 2025-12-19 | Cole Pinnow | Chief Commercial Officer | MIXED | — | — |
| 2025-12-19 | John Edward Robinson | Chief Scientific Officer | MIXED | — | — |
| 2025-10-03 | Karen Jean Ferrante | Director | A | — | — |
| 2025-07-14 | Fairmount Funds Management LLC | Director | Buy | — | — |
| 2025-07-02 | Karen Jean Ferrante | Director | A | — | — |
| 2025-06-05 | CHRISTOPHER W. CAIN | Director | A | — | — |
| 2025-06-05 | Peter Evan Harwin | Director | A | — | — |
| 2025-06-05 | Todd Shegog | Director | A | — | — |
| 2025-06-05 | Arlene Morris | Director | A | — | — |
| 2025-06-05 | Karen Jean Ferrante | Director | A | — | — |
| 2025-06-05 | Matthew Ros | Director | A | — | — |
| 2025-04-03 | Karen Jean Ferrante | Director | A | — | — |
| 2025-01-27 | John Edward Robinson | Chief Scientific Officer | A | — | — |
| 2025-01-27 | Jessica Sachs | Chief Medical Officer | A | — | — |
| 2025-01-27 | Andrew R Robbins | President and CEO | A | — | — |
| 2025-01-27 | John L. Green | Chief Financial Officer | A | — | — |
| 2025-01-27 | Cole Pinnow | Chief Commercial Officer | A | — | — |
| 2025-01-27 | Evan Kearns | Chief Legal Officer | A | — | — |
| 2025-01-15 | Cole Pinnow | Chief Commercial Officer | Buy | — | — |
| 2025-01-03 | Karen Jean Ferrante | Director | A | — | — |
| 2024-10-02 | Karen Jean Ferrante | Director | A | — | — |
| 2024-07-02 | Karen Jean Ferrante | Director | A | — | — |
| 2024-06-13 | Matthew Ros | Director | A | — | — |
| 2024-06-13 | Karen Jean Ferrante | Director | A | — | — |
| 2024-06-13 | Peter Evan Harwin | Director | A | — | — |
| 2024-06-13 | Todd Shegog | Director | A | — | — |
| 2024-06-13 | CHRISTOPHER W. CAIN | Director | A | — | — |
| 2024-06-13 | Arlene Morris | Director | A | — | — |
| 2024-06-12 | Fairmount Funds Management LLC | Director | M | — | — |
| 2024-05-29 | Cole Pinnow | Chief Commercial Officer | A | — | — |
| 2024-04-02 | Karen Jean Ferrante | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 5,503,418 | — |
| — | 10%+ Owner | 1,139,569 | — |
| — | President and CEO | 657,503 | — |
| — | Chief Scientific Officer | 140,002 | — |
| — | Chief Medical Officer | 133,938 | — |
| — | Chief Financial Officer | 131,834 | — |
| — | Chief Legal Officer | 109,398 | — |
| — | Chief Commercial Officer | 97,450 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the COGT quote page; the site-wide leaderboard is on the insider transactions hub.